214139-26-1 Usage
Uses
Used in Pharmaceutical Industry:
N-BOC-D,L-1-AMINOINDANE-1-CARBOXYLIC ACID is used as an intermediate for the synthesis of N-[(chlorophenyl)methyl]oxo[[[(phenylacetyl)amino]methyl]cyclohexyl]piperazinyl]ethyl amide derivatives. These derivatives act as human melanocortin-4 receptor ligands, which have potential applications in the treatment of various conditions related to the melanocortin system, such as obesity, sexual dysfunction, and pigmentation disorders.
The compound's role as an intermediate in the pharmaceutical industry highlights its importance in the development of novel therapeutic agents targeting the melanocortin-4 receptor. Its chemical properties and structural characteristics make it a valuable component in the synthesis of these derivatives, contributing to the advancement of medical treatments for a range of health issues.
Check Digit Verification of cas no
The CAS Registry Mumber 214139-26-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,4,1,3 and 9 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 214139-26:
(8*2)+(7*1)+(6*4)+(5*1)+(4*3)+(3*9)+(2*2)+(1*6)=101
101 % 10 = 1
So 214139-26-1 is a valid CAS Registry Number.
InChI:InChI=1/C15H19NO4/c1-14(2,3)20-13(19)16-15(12(17)18)9-8-10-6-4-5-7-11(10)15/h4-7H,8-9H2,1-3H3,(H,16,19)(H,17,18)/p-1/t15-/m0/s1
214139-26-1Relevant articles and documents
COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
-
Page/Page column 74, (2017/07/19)
The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations with other pharmace
Design and synthesis of certain substituted cycloalkanecarboxamides structurally related to safinamide with anticonvulsant potential
Aboul-Enein, Mohamed N.,El-Azzouny, Aida A.,Maklad, Yousreya A.,Ismail, Mohamed A.,Ismail, Nasser S. M.,Hassan, Rasha M.
, p. 3767 - 3791 (2015/06/08)
A series of novel safinamide derivatives were synthesized and biologically evaluated for their anticonvulsant activity against maximal electroshock seizure assay and subcutaneous pentylenetetrazole (s.c. PTZ) screening test. Compound 13b is the most active derivative in s.c. PTZ screening test with an ED50 value lower than that of safinamide by about tenfold. A molecular modeling study, including fitting to sodium channel blockers 3D-pharmacophore model and docking into a branched-chain aminotransferase enzyme active site were consistent with the in vivo results.
